<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>New Jersey Mesothelioma Lawyers &#124; Philadelphia Mesothelioma Lawyers&#187; Medical</title>
	<atom:link href="http://www.mesotheliomalegalblog.com/mesothelioma/f1-mesothelioma-medical-resources/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.mesotheliomalegalblog.com</link>
	<description>New Jersey Mesothelioma Legal News, Asbestos Litigation, Mesothelioma Compensation, What Is Mesothelioma and more.</description>
	<lastBuildDate>Thu, 02 Feb 2012 20:49:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Protein Test Developed By NYU Shows Promise For Early Detection of Mesothelioma</title>
		<link>http://www.mesotheliomalegalblog.com/2011/04/protein-test-developed-by-nyu-shows-promise-for-early-detection-of-mesothelioma/</link>
		<comments>http://www.mesotheliomalegalblog.com/2011/04/protein-test-developed-by-nyu-shows-promise-for-early-detection-of-mesothelioma/#comments</comments>
		<pubDate>Tue, 26 Apr 2011 19:36:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mesothelioma Research]]></category>

		<guid isPermaLink="false">http://www.mesotheliomalegalblog.com/?p=848</guid>
		<description><![CDATA[On April 4, 2011 researchers at NYU Langone Medical Center presented a study at the American Association for Cancer Research 102nd Annual Meeting held in Orlando, Florida, which detailed their findings on a protein test that may be used to detect early-stage, asbestos-related pulmonary disease.  According to researchers, the test can accurately identify proteins secreted [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.mesotheliomalegalblog.com/wp-content/uploads/2010/01/asbestos_found_in_new_york_buildings.jpg"><img class="alignleft size-full wp-image-161" style="border: 0pt none; margin: 5px;" title="asbestos_found_in_new_york_buildings" src="http://www.mesotheliomalegalblog.com/wp-content/uploads/2010/01/asbestos_found_in_new_york_buildings.jpg" alt="asbestos has been found in buildings throughout new york city" width="150" height="100" /></a>On April 4, 2011 researchers at NYU Langone Medical Center presented a study at the American Association for Cancer Research 102<sup>nd</sup> Annual Meeting held in Orlando, Florida, which detailed their findings on a protein test that may be used to detect early-stage, asbestos-related pulmonary disease.  According to researchers, the test can accurately identify proteins secreted from cancerous tumors caused by asbestos exposure.</p>
<p>Dr Harvey Pass, director of the Division of Thoracic Surgery and Thoracic Oncology at NYU Langone Medical Center and the NYU Cancer Institute, spoke about a novel biomarker test that is believed to be the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. In a blinded test the proteomic assay could detect 15 of 19 cases of malignant pleural mesothelioma that were in stage 1 or stage 2, making the test about 80 percent sensitive, a measure of how accurately a test can identify disease. In addition, the specificity of the test was 100 percent.</p>
<p>“The goal of a new diagnostic test is to find the cancer early enough to effectively treat it”, according to Harvey I. Pass, MD.</p>
<p>To read the full article visit:   <a href="http://communications.med.nyu.edu/news/2011/new-test-detects-early-stage-asbestos-related-pulmonary-cancer">http://communications.med.nyu.edu/news/2011/new-test-detects-early-stage-asbestos-related-pulmonary-cancer</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.mesotheliomalegalblog.com/2011/04/protein-test-developed-by-nyu-shows-promise-for-early-detection-of-mesothelioma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mesothelioma Clinical Trials</title>
		<link>http://www.mesotheliomalegalblog.com/2010/04/mesothelioma-clinical-trials/</link>
		<comments>http://www.mesotheliomalegalblog.com/2010/04/mesothelioma-clinical-trials/#comments</comments>
		<pubDate>Fri, 30 Apr 2010 13:19:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mesothelioma Clinical Trials]]></category>

		<guid isPermaLink="false">http://mesotheliomalegalblog.com/?p=116</guid>
		<description><![CDATA[Here is a listing of the current Mesothelioma Clinical Trials from the National Cancer Institute: Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: IFCT-GFPC-ELCWP-0701, NCT00651456 Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma Phase: Phase III Type: [...]]]></description>
			<content:encoded><![CDATA[<p><img class="alignleft size-full wp-image-164" title="mesothelioma_clinical_trials" src="http://mesotheliomalegalblog.com/wp-content/uploads/2010/04/mesothelioma_clinical_trials.jpg" alt="Mesothelioma Clinical Trials" width="150" height="100" />Here is a listing of the current Mesothelioma Clinical Trials from the National Cancer Institute:</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=594062&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Mesothelioma Avastin Plus Pemetrexed-cisplatin Study</a><br />
Phase: Phase III, Phase II<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 to 75<br />
Sponsor: Other<br />
Protocol IDs: IFCT-GFPC-ELCWP-0701, NCT00651456</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=447218&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma</a><br />
Phase: Phase III<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Pharmaceutical / Industry<br />
Protocol IDs: 2005_010, MK0683-014, NCT00128102</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=536483&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase III Randomized Study of an Electronic Tool for Monitoring Symptoms and Syndromes Associated With Advanced Cancer (E-MOSAIC) in Patients With Advanced Incurable Cancer Receiving Palliative Anticancer Treatment</a><br />
Phase: Phase III<br />
Type: Health services research<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: SWS-SAKK-95/06, SAKK-95/06, EU-20711, SWS-SAKK-E-MOSAIC, NCT00477919</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=581128&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase III Randomized Study of Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Who are Opioid Tolerant</a><br />
Phase: Phase III<br />
Type: Supportive care<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Pharmaceutical / Industry<br />
Protocol IDs: INSYS-INS-05-001, INS-05-001, NCT00538850, NCT00538850</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=583642&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase III Study of Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Who are Opioid Tolerant</a><br />
Phase: Phase III<br />
Type: Supportive care<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Pharmaceutical / Industry<br />
Protocol IDs: INSYS-INS-06-007, INS-06-007, NCT00538863</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=630699&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase III Randomized Study of Video-Assisted Thoracoscopic Cytoreductive Pleurectomy Versus Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma</a><br />
Phase: Phase III<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: PAPWORTH-MESOVATS, MESOVATS, PAPWORTH-P00804, EU-20901, ISRCTN34321019, NCT00821860</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=670088&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed</a><br />
Phase: Phase III<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Pharmaceutical / Industry<br />
Protocol IDs: NGR015, 2009-016879-29, NCT01098266</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=599406&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)</a><br />
Phase: Phase II, Phase I<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Pharmaceutical / Industry<br />
Protocol IDs: CBP08-01, NCT00700336</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=601972&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Multiple Respiration-Correlated Cone Beam Computed Tomography (CT) Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer</a><br />
Phase: Phase II, Phase I<br />
Type: Diagnostic<br />
Status: Active<br />
Age: Over 18<br />
Sponsor: Other<br />
Protocol IDs: 08-080, NCT00722605</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=629030&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Short Neoadjuvant Hemithoracic IMRT for MPM</a><br />
Phase: Phase II, Phase I<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: 08-0106-C, NCT00797719</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=665415&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase I/II Randomized Study of Pemetrexed Disodium and Cisplatin With Versus Without Cediranib Maleate in Patients With Malignant Pleural Mesothelioma</a><br />
Phase: Phase II, Phase I<br />
Type: Treatment<br />
Status: Approved-not yet active<br />
Age: 18 and over<br />
Sponsor: NCI<br />
Protocol IDs: SWOG-S0905, S0905, NCT01064648</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=441648&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence</a><br />
Phase: Phase II<br />
Type: Diagnostic<br />
Status: Active<br />
Age: 15 and over<br />
Sponsor: Other<br />
Protocol IDs: SP-14-0038, NCT00123773</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=448939&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate</a><br />
Phase: Phase II<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: 04-063, NCT00165503</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=463521&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery</a><br />
Phase: Phase II<br />
Type: Biomarker/Laboratory analysis, Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: NCI<br />
Protocol IDs: UCCRC-14203B, NCI-7103, 7103, NCT00309946</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=471802&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma</a><br />
Phase: Phase II<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: AVF3442S, NCT00295503</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=481153&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase II Randomized Study of Neoadjuvant Therapy With Pemetrexed Disodium and Cisplatin Followed By Extrapleural Pneumonectomy With or Without Postoperative Hemithoracic Radiotherapy in Patients With Malignant Pleural Mesothelioma</a><br />
Phase: Phase II<br />
Type: Biomarker/Laboratory analysis, Treatment<br />
Status: Active<br />
Age: 18 to 69<br />
Sponsor: Other, Pharmaceutical / Industry<br />
Protocol IDs: SWS-SAKK-17/04, EU-20615, EUDRACT-2006-000445-19, LILLY-SAKK-17/04, NCT00334594</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=526027&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma<br />
Phase: Phase II</a><br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: ONC-2006-003, EUDRACT 2006-004429-27, NCT00407459</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=538677&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase II Study of Bortezomib and Cisplatin as First-Line Treatment in Patients With Malignant Mesothelioma<br />
Phase: Phase II</a><br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other, Pharmaceutical / Industry<br />
Protocol IDs: EORTC-08052, JJPRD-26866138CAN2012, EUDRACT-2006-000009-51, 08052, NCT00458913</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=542754&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis<br />
Phase: Phase II</a><br />
Type: Treatment<br />
Status: Active<br />
Age: 20 to 70<br />
Sponsor: Other<br />
Protocol IDs: WUCC-0701, NCT00454519</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=549457&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Tomotherapy Treatment for Mesothelioma</a><br />
Phase: Phase II<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: LU-11-0077, NCT00469196</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=560151&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase II Study of Bortezomib in Patients With Malignant Pleural Mesothelioma</a><br />
Phase: Phase II<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: ICORG-05-10, ICORG-05-10, EUDRACT-2005-004420-39, EU-20748, NCT00513877</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=564058&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Phase II Study of Pemetrexed Disodium, Cisplatin, and Vitamin B12 in Patients With Unresectable Pleural Mesothelioma</a><br />
Phase: Phase II<br />
Type: Biomarker/Laboratory analysis, Supportive care, Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: COL-ALIMESO, ALIMESO, INCA-RECF0441, COL-2006-04, NCT00541073</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=575546&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma</a><br />
Phase: Phase II<br />
Type: Treatment<br />
Status: Approved-not yet active<br />
Age: 18 to 75<br />
Sponsor: Other<br />
Protocol IDs: GIMe/01/06, NCT00551252</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=597371&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma</a><br />
Phase: Phase II<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Pharmaceutical / Industry<br />
Protocol IDs: TL139204, NCT00685204</p>
<p><a title="Mesothelioma Clinical Trial Information" href="http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=601185&amp;version=HealthProfessional&amp;protocolsearchid=7599932" target="_blank">Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma</a><br />
Phase: Phase II<br />
Type: Treatment<br />
Status: Active<br />
Age: 18 and over<br />
Sponsor: Other<br />
Protocol IDs: 08-053, NCT00715611</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mesotheliomalegalblog.com/2010/04/mesothelioma-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mesothelioma Support Groups</title>
		<link>http://www.mesotheliomalegalblog.com/2010/03/mesothelioma-support-groups/</link>
		<comments>http://www.mesotheliomalegalblog.com/2010/03/mesothelioma-support-groups/#comments</comments>
		<pubDate>Sun, 28 Mar 2010 19:15:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mesothelioma Support]]></category>

		<guid isPermaLink="false">http://www.mesotheliomalegalblog.com/?p=571</guid>
		<description><![CDATA[I have provided a list of support groups for victims of mesothelioma: http://www.acor.org/support.html &#8211; Association of Cancer Online Resources (ACOR) manages a mailing list for mesothelioma patients. http://www.alcase.org/support/suptrgroups.html &#8211; Alliance for Lung Cancer, Advocacy, Support and Education Support Groups (ALCASE) national lung cancer support groups. http://www.aicr.org/resource.html - American Institute for Cancer Research (AICR) Cancer Resource [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.mesotheliomalegalblog.com/wp-content/uploads/2010/03/caregivers-and-families.jpg"><img src="http://www.mesotheliomalegalblog.com/wp-content/uploads/2010/03/caregivers-and-families-150x150.jpg" alt="" title="caregivers-and-families" width="150" height="150" class="alignleft size-thumbnail wp-image-626" /></a>I have provided a list of support groups for victims of mesothelioma:</p>
<p><a href="http://www.acor.org/support.html">http://www.acor.org/support.html</a> &#8211; Association of Cancer Online Resources (ACOR) manages a mailing list for mesothelioma patients.</p>
<p><a href="http://www.alcase.org/support/suptrgroups.html">http://www.alcase.org/support/suptrgroups.html</a> &#8211; Alliance for Lung Cancer, Advocacy, Support and Education Support Groups (ALCASE) national lung cancer support groups.</p>
<p><a href="http://www.aicr.org/resource.html ">http://www.aicr.org/resource.html </a>- American Institute for Cancer Research (AICR) Cancer Resource provides treatment information to cancer patients and their families.</p>
<p><a href="http://www.cancercare.org/people/counseling">http://www.cancercare.org/people/counseling</a> &#8211; Cancer Care Counseling provides free professional counseling for individuals or professionally facilitated support groups.</p>
<p><a href="http://www.amc.org/flash/cicl/f_cicl_aboutcicl.html">http://www.amc.org/flash/cicl/f_cicl_aboutcicl.html</a> &#8211; Cancer Information and Counseling Line (CICL) is a service of AMC Cancer Center to help people with cancer and their families.</p>
<p><a href="http://www.hospiceworld.org/">http://www.hospiceworld.org/</a> &#8211; Hospicelink not-for-profit organization that offers information about hospice and palliative care. They can refer patients and their families to local programs.</p>
<p><a href="http://www.wellness-community.org/">http://www.wellness-community.org/</a> &#8211; National program of education, support and hope for cancer patients and their families.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mesotheliomalegalblog.com/2010/03/mesothelioma-support-groups/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Reason to Hope for New Jersey &amp; Pennsylvania Mesolthelioma Patients</title>
		<link>http://www.mesotheliomalegalblog.com/2009/10/more-reason-to-hope-for-new-jersey-pennsylvania-mesolthelioma-patients/</link>
		<comments>http://www.mesotheliomalegalblog.com/2009/10/more-reason-to-hope-for-new-jersey-pennsylvania-mesolthelioma-patients/#comments</comments>
		<pubDate>Sat, 31 Oct 2009 01:16:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mesothelioma Research]]></category>
		<category><![CDATA[Mesothelioma Treatment Options]]></category>

		<guid isPermaLink="false">http://mesotheliomalegalblog.com/?p=92</guid>
		<description><![CDATA[The news for mesothelioma treatment continues reason for hope. Drug researchers from China and the United States are working together on the KDR/Kit Inhibitor, which will work to end the new growth of cancerous cells in patients. The two companies, China-based Simcere Pharmaceutical Group and OSI Pharmaceuticals in the U.S., are basing the project in [...]]]></description>
			<content:encoded><![CDATA[<p>The news for mesothelioma treatment continues reason for hope.  Drug researchers from China and the United States are working together on the KDR/Kit Inhibitor, which will work to end the new growth of cancerous cells in patients.</p>
<p>The two companies, China-based Simcere Pharmaceutical Group and OSI Pharmaceuticals in the U.S., are basing the project in China. OSI specializes in the discovery and development of innovative molecular targeted therapies. The drug, called OSI-930 for now, has shown positive results in treating small and non-small cell <a class="tak_filtered" href="http://www.asbestos.net/lung-cancer/">lung cancer</a>, colorectal, gastric and other cancers. Its effectiveness in treating these cancers has the teams working on its treatment of mesothelioma as well.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mesotheliomalegalblog.com/2009/10/more-reason-to-hope-for-new-jersey-pennsylvania-mesolthelioma-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Clinical Trials for Mesothelioma Patients</title>
		<link>http://www.mesotheliomalegalblog.com/2009/07/new-clinical-trials-for-mesothelioma-patients/</link>
		<comments>http://www.mesotheliomalegalblog.com/2009/07/new-clinical-trials-for-mesothelioma-patients/#comments</comments>
		<pubDate>Sun, 19 Jul 2009 18:51:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mesothelioma Clinical Trials]]></category>

		<guid isPermaLink="false">http://mesotheliomalegalblog.com/?p=64</guid>
		<description><![CDATA[The Dana-Farber Cancer Institute at Brigham and Women&#8217;s Hospital in Boston is currently searching for mesothelioma patients to take part in a clinical trial that will study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. This Phase I [...]]]></description>
			<content:encoded><![CDATA[<p>The Dana-Farber Cancer Institute at Brigham and Women&rsquo;s Hospital in Boston is currently searching for mesothelioma patients to take part in a clinical trial that will study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. This Phase I trial will also research the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.</p>
<p>The study, which will be completed in 2010, will also involve the surgical procedure known as extrapleural pneumonectomy or pleurectomy/decortication, which includes the resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm). The chemotherapy drugs will be administered immediately following the surgery. <br />
&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mesotheliomalegalblog.com/2009/07/new-clinical-trials-for-mesothelioma-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ONCONASE May Provide Significant Efficacy in Patients with Malignant Mesothelioma</title>
		<link>http://www.mesotheliomalegalblog.com/2009/07/onconase-may-provide-significant-efficacy-in-patients-with-malignant-mesothelioma/</link>
		<comments>http://www.mesotheliomalegalblog.com/2009/07/onconase-may-provide-significant-efficacy-in-patients-with-malignant-mesothelioma/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 16:48:49 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Mesothelioma Research]]></category>

		<guid isPermaLink="false">http://mesotheliomalegalblog.com/?p=62</guid>
		<description><![CDATA[As reported in http://www.medicalnewstoday.com/articles/124975.php &#160; Alfacell Corporation (Nasdaq: ACEL) announced that a paper published in Cell Cycle (2008; Vol. 7, Issue 20) reports that ONCONASE (ranpirnase) targets small interfering RNA (siRNA), likely within the RNA-induced silencing complex (RISC) of the RNA interference (RNAi) mechanism. The paper is the result of research conducted by collaborators at [...]]]></description>
			<content:encoded><![CDATA[<p>As reported in <a href="http://www.medicalnewstoday.com/articles/124975.php">http://www.medicalnewstoday.com/articles/124975.php</a></p>
<p>&nbsp;</p>
<p>Alfacell Corporation (Nasdaq: ACEL) announced that a paper published in Cell Cycle (2008; Vol. 7, Issue 20) reports that ONCONASE (ranpirnase) targets small interfering RNA (siRNA), likely within the RNA-induced silencing complex (RISC) of the RNA interference (RNAi) mechanism.</p>
<p>The paper is the result of research conducted by collaborators at the Brander Cancer Research Institute and Department of Pathology at New York Medical College and Alfacell. The study demonstrated that silencing the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene (an abundant and ubiquitously expressed housekeeping gene) in human lung adenocarcinoma A549 cells by siRNA was effectively prevented by ONCONASE. While transfection of cells with GAPDH siRNA reduced expression of this protein by nearly 70 percent, the expression was restored in the cells exposed to ONCONASE for 48 or 72 hours. The data thus provide evidence that one of the targets of ONCONASE (ranpirnase) is siRNA.</p>
<p>&quot;This data provide further evidence of the impact of ONCONASE on the RNAi mechanism,&quot; said Kuslima Shogen, Alfacell&#8217;s chief executive officer. &quot;Furthermore, the data may provide the explanation for the preferential effectiveness of ONCONASE toward tumor cells as well as its ability to sensitize cells to other antitumor agents. As seen in our Phase III clinical trial results, ONCONASE has demonstrated significant efficacy in patients with malignant mesothelioma that failed prior chemotherapy.&quot;<br />
&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mesotheliomalegalblog.com/2009/07/onconase-may-provide-significant-efficacy-in-patients-with-malignant-mesothelioma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mesothelioma Treatment Centers by State</title>
		<link>http://www.mesotheliomalegalblog.com/2009/05/mesothelioma-treatment-centers-by-state/</link>
		<comments>http://www.mesotheliomalegalblog.com/2009/05/mesothelioma-treatment-centers-by-state/#comments</comments>
		<pubDate>Sun, 31 May 2009 01:39:19 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Locate a Medical Specialist]]></category>
		<category><![CDATA[Mesothelioma Experts]]></category>
		<category><![CDATA[Mesothelioma Surgery Centers]]></category>
		<category><![CDATA[Mesothelioma Treatment Options]]></category>

		<guid isPermaLink="false">http://mesotheliomalegalblog.com/?p=31</guid>
		<description><![CDATA[// Treatment Centers for Patients with Mesothelioma UAB Comprehensive Cancer Center 1824 6th Avenue South Birmingham, AL 1-(800)-UAB-0933 UAB Comprehensive Cancer Center is one of the nation&#8217;s leading cancer research and treatment centers, and is the only National Cancer Institute-designated comprehensive cancer center located in a six-state area that includes Alabama, Mississippi, Louisiana, Arkansas, South [...]]]></description>
			<content:encoded><![CDATA[<p><script type="text/javascript">// <![CDATA[
function MM_openBrWindow(theURL,winName,features) { //v2.0
  window.open(theURL,winName,features);
}
// ]]&gt;</script></p>
<p><span style="font-size: x-large;">Treatment Centers for Patients with Mesothelioma</span></p>
<p>UAB Comprehensive Cancer Center<br />
1824 6th Avenue South<br />
Birmingham, AL<br />
1-(800)-UAB-0933</p>
<p><a href="http://www3.ccc.uab.edu/">UAB Comprehensive Cancer Center</a> is one of the nation&#8217;s leading cancer research and treatment centers, and is the only National Cancer   Institute-designated comprehensive cancer center located in a six-state   area that includes Alabama, Mississippi, Louisiana, Arkansas, South   Carolina and Georgia. UAB&#8217;s cancer services are routinely recognized as   being among the nation&#8217;s best.</p>
<p>Arizona Cancer Center<br />
1515 North Campbell Ave.<br />
Tucson, AZ 85724-5024<br />
1-(800)-622-COPE</p>
<p><a href="http://www.amh.org">Arizona Cancer Center</a> is one of 40 centers in the nation and the only one   headquartered in and serving the entire state of Arizona that has been   designated by the National Cancer Institute as a Comprehensive Cancer   Center, the NCI’s highest ranking. That designation is reserved for   centers focusing on patient care as well as basic and clinical research,   prevention, education, outreach and training.</p>
<p>Chao Family Comprehensive Cancer Center<br />
101 The City Drive, Bldg, 23<br />
Route 81<br />
Orange, CA 92868<br />
1-(714)-456-8200</p>
<p><a href="http://www.cancer.uci.edu/about.html">Chao Family Comprehensive Cancer Center</a> is located on the <a href="http://www.healthcare.uci.edu/">UC Irvine   Medical Center</a> campus. The Comprehensive Cancer Center   is affiliated with the <a href="http://www.som.uci.edu/" target="_blank">School   of Medicine </a>at the University of California, Irvine. As a   university-based facility, the cancer center offers the expertise of a   scientific community that is internationally renowned for its work in   the prevention, diagnosis and treatment of cancer.</p>
<p>Dr. David Jablons<br />
UCSF Cancer Center<br />
1600 Divisadero Street<br />
San Francisco, CA 94115<br />
1-(415)-885-3882</p>
<p><a href="http://cancer.ucsf.edu/">UCSF Cancer Center</a>&#8216;s long tradition of excellence in cancer research includes,   notably, the Nobel Prize-winning work of J. Michael Bishop and Harold   Varmus, who discovered cancer-causing oncogenes. Their work opened new   doors for exploring genetic mistakes that cause cancer, and formed the   basis for some of the most important cancer research happening today.</p>
<p>Dr. Kim Kerstine<br />
City of Hope/Beckman Research Institute<br />
1500 East Duarte Road<br />
Duarte, CA. 91010<br />
1-(800)-826-HOPE</p>
<p><a href="http://www.cityofhope.org/Pages/default.aspx">City of Hope/Beckman Research Institute</a> is a national cancer institute (NCI)-designated comprehensive cancer   center that offers a full complement of services   designed to address all aspects of cancer, from understanding its   origins, to developing new therapies and testing them in patient   clinical trials, to delivering superior patient care and providing   support and education to patients, their families and the public.</p>
<p>Dr. Robert Cameron<br />
UCLA Surgery<br />
10833 Le Conte Ave<br />
Los Angeles, CA. 90095<br />
1-(310)-794-7333</p>
<p><a href="http://www.surgery.ucla.edu/">UCLA Surgery&#8217;s </a>Thoracic Surgery website provides   information on  general thoracic surgery,   lung diseases,   lung cancer,   metastatic tumors (sarcomas, colon cancer, etc.),   lung volume reduction surgery (emphysema surgery),   minimally-invasive and robotic-assisted lung surgery,   esophageal diseases,   esophageal cancer,   acid reflux surgery,   achalasia and esophageal motility disorders,   hiatal hernia repair,   minimally-invasive and robotic-assisted esophageal surgery,   pleural diseases,   mesothelioma,   lung-sparing surgery,   biologic therapy,   chest wall diseases,   sarcomas,   pectus Excavatum,   pectus Carinatum,   chest wall reconstruction,   mediastinal diseases,   thymoma,   neurogenic tumors,   minimally-invasive and robotic-assisted surgery,   minimally invasive thoracic surgery,   robotic-assisted thoracic surgery,   surgical adjuvant therapy,   immunology,   biologic therapy and  anti-angiogenic therapy.</p>
<p>Jonsson Comprehensive Cancer Center<br />
8-684 Factor Building<br />
Los Angeles, CA. 90095-1781<br />
1-(310)-825-5268</p>
<p><a href="http://www.cancer.ucla.edu/">Jonsson Comprehensive Cancer Center</a> is a renowned cancer research and cancer diagnosis, treatment and prevention center, specializing in mesothelioma. Located at the University of California Los Angeles.</p>
<p>Rebecca and John Moores UCSD Cancer Center<br />
3855 Health Sciences Drive<br />
La Jolla, CA. 92093<br />
1-(858)-822-1222</p>
<p><a href="http://cancer.ucsd.edu/PatientCare/ClinicalTrials/study_details.asp?P=6822">Rebecca and John Moores UCSD Cancer Center </a>focuses on research, outreach and prevention, and offers clinical trials focusing in on the treatment of mesothelioma. Located in San Diego, California.</p>
<p>USC/Norris Comprehensive Cancer Center<br />
1441 Eastlake Avenue<br />
Los Angeles, CA. 90033<br />
1-(800)-USC-CARE</p>
<p><a href="http://ccnt.hsc.usc.edu/">USC/Norris Comprehensive Cancer Center</a> is a leader in cancer research, with nearly 200 members investigating the complex origins and progression of cancer, developing prevention strategies and searching for cures. USC Norris is part of the Keck School of Medicine and is designated by the National Cancer Institute as one of the nation&#8217;s 40 comprehensive cancer centers.</p>
<p>University of Colorado Cancer Center<br />
1665 N. Ursula St.<br />
Aurora, CO. 80045<br />
1-(800)-473-2288</p>
<p><a href="http://www.uccc.info/for-healthcare-professional/cancer-center/index.aspx">University of Colorado Cancer Center</a> is  the Rocky Mountain region’s only   National Cancer Institute-designated comprehensive cancer center<strong>.</strong>Headquartered on the Anschutz Medical Campus, UCCC is a <strong>consortium</strong> of three state universities and five institutions.</p>
<p>Yale Cancer Center<br />
333 Cedar Street<br />
New Haven, CT. 06520-8028<br />
1-(203)-785-4095</p>
<p><a href="http://www.yalecancercenter.org/">Yale Cancer Center</a> is southern New England&#8217;s only cancer center   designated as a Comprehensive Cancer Center by the National Cancer   Institute- and one of only 40 in the nation.  The significance of this   designation has profound implications for those who choose Yale as the   place where they will be cared for and receive treatment for their   cancer.  National Cancer Institute cancer centers are national leaders   in cancer research, prevention, detection, and treatment.  This provides   patients at Yale Cancer Center with novel treatment options and expert   care.</p>
<p>Dr. Paul Sugarbaker<br />
Washington Cancer Institute<br />
106 Irving Street NW, Suite 3900N<br />
Washington, D.C.20010<br />
1-(202)-877-3908</p>
<p><a href="http://www.whcenter.org/body.cfm?id=191">Washington Cancer Institute</a> at the Washington Cancer Institute at   Washington Hospital Center offers advanced services to include specialty   treatment programs for gastric cancer, pseudomyxoma peritonei,   hepatobiliary (primary and metastatic liver cancer), pancreas cancer, as   well as primary peritoneal surface malignancies such as abdominopelvic   sarcoma. The center provides services for the following areas: appendix, colorectal with peritoneal carcinomatosis   (cancers that spread to the intra-abdominal surfaces), and peritoneal mesothelioma</p>
<p>Lombardi Comprehensive Cancer Center<br />
38 Reservoir Road NW<br />
Washington, D.C.20057<br />
1-(202)-784-4000</p>
<p><a href="http://lombardi.georgetown.edu/patient/diseases/lung/mesothelioma/">Lombardi Comprehensive Cancer Center</a> clinicians are dedicated to  providing the best professional care,   delivered with compassion, for  all patients. Lombardi&#8217;s internationally-renowned   physicians treat  virtually every type of cancer, including breast,   lung, colorectal,  prostate, head and neck, and cancers of the blood.   Along with  cutting-edge cancer care, we offer a program of innovative   clinical  trials and a full range of supportive care services to improve   our  patients&#8217; health and quality of life, and Lombardi specializes in the care of malignant mesothelioma.</p>
<p>Dr. Larry Robinson<br />
Moffitt Cancer Center Institute<br />
12902 Magnolia Dr<br />
Tampa, FL. 33612<br />
1-(813)-972-8412</p>
<p><a href="http://www.moffitt.org/totalcancercare">Moffitt Cancer Center Institute </a> is an ambitious partnership between patients, doctors and researchers to   improve all aspects of cancer prevention and care.  Patients participate   by donating <strong>information</strong> and <strong>tissue</strong>. Researchers   use the information to learn about  all <strong>issues related to   cancer</strong> and how care can be improved.  Clinicians use the   information to better educate and care for patients.</p>
<p>Dr. Hedy Lee Kindler<br />
University of Chicago Hospitals<br />
5841 S. Maryland Avenue<br />
Chicago, IL. 60637<br />
1-(773)-702-0360</p>
<p><a href="http://www.uchospitals.edu/specialties/cancer/mesothelioma/">University of Chicago Hospitals </a>has been a pioneer   in the study and treatment of malignant mesothelioma&#8211;a rare disease   that affects 2,500 to 3,000 people in the United States each year. Their program is comprised of a dedicated team of medical oncologists,   surgeons, nurses, pathologists, imaging specialists, and scientists who   understand the unique characteristics of this disease. The University of Chicago Hospitals use a team   approach with weekly mesothelioma program meetings. Their comprehensive   and multidisciplinary focus is a direct reflection of our clinical   interest in mesothelioma and their expertise is in developing novel treatment   protocols that extend lives.</p>
<p>Robert H. Lurie Cancer Center<br />
Northwestern University<br />
675 N. St. Clair, Galter Pavilion – 21st Floor<br />
Chicago, IL. 60611<br />
1-(312)-908-5250</p>
<p><a href="http://www.cancer.northwestern.edu/home/index.cfm">Robert H. Lurie Cancer Center</a> is committed to being a national leader in the   battle to overcome cancer. To this end, Chicago&#8217;s Lurie Cancer Center is   dedicated to scientific discovery, advancing medical knowledge,   providing compassionate, state-of-the-art cancer care, and training the   next generation of clinicians and scientists</p>
<p>Dana-Farber Cancer Institute<br />
44 Binney Street<br />
Boston, MA. 02115<br />
1-(800)-320-0022</p>
<p><a href="http://www.dana-farber.org/pat/adult/treatment-centers/Mesothelioma_Malignant.html">Dana-Farber Cancer Institute</a> offers care for mesothelioma; malignant patients at Dana-Farber is provided   through the Thoracic Cancer Treatment Center.  Read about services and   clinical research, and see a list of medical staff.</p>
<p>Dr. David J. Sugarbaker<br />
Brigham and Women&#8217;s Hospital<br />
75 Francis Street<br />
Boston, MA. 02115<br />
1-(617)-732-6824</p>
<p><a href="http://www.brighamandwomens.org/mesothelioma/About_Mesothelioma.aspx?subID=submenu2">Brigham and Women&#8217;s Hospital</a> is world-renowned in virtually every area   of adult medicine. As a teaching hospital of Harvard Medical School, their   leadership in patient quality and safety, development of   state-of-the-art treatments and technologies, and robust research   programs have improved the health of people around the world. They offer extensive information on the treatment of mesothelioma.</p>
<p>Dr. Mark Krasna<br />
University of Maryland Greenebaum Cancer Center<br />
22 S Greene Street<br />
Baltimore, MD 21201<br />
1-(410)-328-6366</p>
<p><a href="http://www.umgcc.org/thoracic_program/approach_mesoth.htm#1">University of Maryland Greenebaum Cancer Center</a> offers modern       therapy of mesothelioma, with surgery and chemotherapy   as central stage treatment options.. The Cancer Center offers patients hope, with a better understanding of its   cellular       and molecular pathogenesis novel treatment approach.</p>
<p>Dr. Mark Krasna<br />
Johns Hopkins Oncology Center<br />
401 North Broadway<br />
Baltimore, MD 21231<br />
1-(410)-614-3891</p>
<p><a href="http://www.amh.org">Johns Hopkins Oncology Center</a> is a   fully accredited, not-for-profit, regional teaching hospital. Located at   1200 Old York Road (Route 611) in Abington, PA, AMH has been providing   comprehensive, high-quality services for people in Montgomery, Bucks and   Philadelphia counties for more than 90 years.</p>
<p>Barbara Ann Karmanos Cancer Institute<br />
4100 John R<br />
Detroit, Michigan 48201<br />
1-(800)-KARMANOS</p>
<p><a href="http://www.amh.org">Barbara Ann Karmanos Cancer Institute</a> is a   fully accredited, not-for-profit, regional teaching hospital. Located at   1200 Old York Road (Route 611) in Abington, PA, AMH has been providing   comprehensive, high-quality services for people in Montgomery, Bucks and   Philadelphia counties for more than 90 years.</p>
<p>Dr. Gregory Kalemkerian<br />
University Michigan Cancer Center<br />
1500 E. Medical Center Drive<br />
Ann Arbor, MI. 48109<br />
1-(734)-936-5281</p>
<p><a href="http://www.amh.org">University Michigan Cancer Center</a> is a   fully accredited, not-for-profit, regional teaching hospital. Located at   1200 Old York Road (Route 611) in Abington, PA, AMH has been providing   comprehensive, high-quality services for people in Montgomery, Bucks and   Philadelphia counties for more than 90 years.</p>
<p>Mayo Clinic Cancer Center<br />
200 First Street SW<br />
Rochester, MN. 55905<br />
1-(507)-284-2111</p>
<p><a href="http://www.amh.org">Mayo Clinic Cancer Center</a> is a   fully accredited, not-for-profit, regional teaching hospital. Located at   1200 Old York Road (Route 611) in Abington, PA, AMH has been providing   comprehensive, high-quality services for people in Montgomery, Bucks and   Philadelphia counties for more than 90 years.</p>
<p>University of Minnesota Cancer Center<br />
420 Delaware St. SE<br />
Minneapolis, MN. 55455<br />
1-(612)-624-8484</p>
<p><a href="http://www.amh.org">University of Minnesota Cancer Center</a> is a   fully accredited, not-for-profit, regional teaching hospital. Located at   1200 Old York Road (Route 611) in Abington, PA, AMH has been providing   comprehensive, high-quality services for people in Montgomery, Bucks and   Philadelphia counties for more than 90 years.</p>
<p>Comprehensive Cancer Center<br />
Wake Forest University<br />
Medical Center Boulevard<br />
Winston-Salem, NC. 27157<br />
1-(800)-446-2255</p>
<p><a href="http://cancercenters.cancer.gov/cancer_centers/wfccc.html">Comprehensive Cancer Center</a> is one of the nation’s oldest NCI-designated cancer centers (1974).  						  CCCWFU recently celebrated its 30th year of delivering quality   patient  						  care, providing education and outreach to individuals at risk   for developing  						  the disease, and achieving excellence in basic science research.</p>
<p>Dr. David Harpole<br />
Duke University Medical Center<br />
Trent Drive<br />
Durham, NC. 27706<br />
1-(919)-668-8413</p>
<p><a href="http://www.cancer.duke.edu/">Duke University Medical Center</a> is one of only 40 centers in the country designated by the National Cancer   Institute (NCI) as a “comprehensive cancer center,” Duke combines   cutting-edge research with compassionate care. Their team of nationally   recognized physicians and staff treat more than 7,000 new patients per   year, giving them the extensive experience that yields better results.   The Duke Comprehensive Cancer Center is ranked as one of the top 10   cancer hospitals in the country, according to U.S.News &amp; World   Report&#8217;s &#8220;America&#8217;s Best Hospitals&#8221; survey.</p>
<p>UNC Lineberger Comprehensive Cancer Center<br />
Manning Drive<br />
Chapel Hill, NC. 27599-7295<br />
1-(919)-966-3036</p>
<p><a href="http://cancer.med.unc.edu/aboutus/">UNC Lineberger Comprehensive Cancer Center</a>, with support from the state of North Carolina for the construction of        the <a href="http://nccancerhospital.org/about.asp">N.C. Cancer   Hospital</a> and        through the <a href="http://ucrf.unc.edu/">University Cancer   Research Fund</a>,        treats cancer patients, conducts research   into the        causes of cancer and searches for new treatments, develops and directs   statewide        programs in cancer prevention, and trains future physicians,   nurses, scientists        and public health professionals.</p>
<p>Dr. Brian W. Loggie<br />
Creighton University Medical Center<br />
2500 California Plaza<br />
Omaha, NE 68178<br />
1-(402)-280-4100</p>
<p><a href="http://www.creightonhospital.com/en-us/aboutus/pages/default.aspx">Creighton University Medical Center</a> is an academic   medical center, teaching tomorrow’s health care professionals while   striving for excellence in mesothelioma and cancer diagnosis and treatment.   Driven   by their passion for patient care, teaching and research, the Creighton University Medical Center provides   advanced care for some of the region’s sickest patients, smallest babies   and most complex injuries and illnesses.  They raise the bar   for clinical experience with their expertise in trauma, cardiac care,   cancer care, specialized surgery, transfusion-free medicine and   high-risk obstetrics.</p>
<p>Norris Cotton Cancer Center<br />
1 Medical Center Drive<br />
Lebanon, NH. 03756<br />
1-(800)-639-6918</p>
<p><a href="http://www.cancer.dartmouth.edu/about/index.shtml">Norris Cotton Cancer Center</a> at Dartmouth-Hitchcock   Medical Center    is one of the nation&#8217;s premier facilities for cancer treatment and   research. It  is one of only 40 National Cancer Institute designated <a href="http://www.cancer.dartmouth.edu/about/nci.shtml">comprehensive   cancer  centers</a> in the United    States, and is rated by <a href="http://www.cancer.dartmouth.edu/media/release/071006.shtml">US   News &amp;  World Report</a> as one of the top 50 hospitals for cancer   care nationally.<br />
The Cancer Center provides a positive environment  for   treatment, cure, and recovery for patients with all forms of cancer.    Patients receive technologically advanced cancer treatments and access   to  clinical trials of new treatments. Each patient is seen as an   individual, and a  specific treatment plan is developed by specialists   who work directly with the  patient, family, and referring physician.   The Cancer Center  is also a leader in improving the comfort and quality   of life of patients.</p>
<p>Dr. Claire F. Verschraegen<br />
UNM Cancer Treatment Center<br />
900 Camino de Salud NE<br />
Albuquerque, NM. 87131<br />
1-(505)-272-4551</p>
<p><a href="http://cancer.unm.edu/">UNM Cancer Treatment Center</a> is <span>the Official Cancer Center of the State of New Mexico, and   the only National Cancer Institute-designated cancer center in the   state. The UNM Cancer Center offers an unmatched depth and breadth of   cancer care in New Mexico.</span><span>They are home to the state’s   largest and most experienced team of cancer specialists, with more than 85 board-certified cancer physicians, representing every area   of oncology, and more than 120 cancer researchers. UNM Cancer Treatment Center has been recruited   from prestigious institutions from all over the world.</span></p>
<p>Cancer Research Center<br />
Albert Einstein College of Medicine<br />
1300 Morris Park Avenue<br />
Bronx, NY. 10461<br />
1-(718)-430-2302</p>
<p><a href="http://www.einstein.yu.edu/cancercenter/page.aspx">Albert Einstein College of Medicine Cancer Research Center</a> was among the first cancer centers on   medical school campuses to be funded by the <a onclick="MM_openBrWindow('http://www.cancer.gov','nci','scrollbars=yes,width=700,height=600')" href="http://www.einstein.yu.edu/cancercenter/page.aspx#">National   Cancer Institute</a> in 1972 following passage of the National Cancer   Act the previous year. AECC has had continuous center funding by the   National Cancer Institute since that time. The goal of AECC is to foster basic,   clinical, and translational research that addresses all aspects of the   cancer problem.  There are programs to cover Epidemiology along with   Cancer Control and Prevention.   <a title="AECC members" href="http://www.einstein.yu.edu/cancercenter/findmember.asp">AECC   members</a> are involved in cancer-relevant research or collaborative   projects with other members whose work has a cancer focus. All AECC   members are supported through approved national peer-reviewed funding   mechanisms. There are currently over 140 AECC members who represent a   broad spectrum of basic and clinical departments.</p>
<p>Dr. Harvey Pass<br />
NYU Comprehensive Cancer Center<br />
530 First Avenue, Suite 9V<br />
New York, NY 10016<br />
1-(212)-263-7417</p>
<p><a href="http://ci.med.nyu.edu/">NYU Comprehensive Cancer Center</a>&#8216;s mission is to discover the origins of   human cancer and to use that knowledge to eradicate the personal and   societal burden of cancer in our community, the nation and the world.  The NYU Cancer Institute takes a multidisciplinary approach to patient   care and features a translational research program that brings together   laboratory scientists and clinical researchers. The result:  the latest   advances in cancer care are delivered in a caring and compassionate   setting.</p>
<p>Dr. Robert N. Taub, MD<br />
NY Presbyterian Medical Center<br />
161 Fort Washington Avenue<br />
New York, NY 10032<br />
1-(212)-305-4076</p>
<p><a href="http://nyp.org/services/oncology/mesothelioma.html">NY Presbyterian Medical Center</a>recently established a Mesothelioma   Center, unique in this area, to provide comprehensive diagnosis and   treatment for this uncommon cancer. Mesothelioma originates in the   membrane lining the abdominal cavity or the chest cavity, and is often   seen in older patients who have been exposed to asbestos. Other causes,   such as radiation and certain viruses, have sometimes been implicated. NewYork-Presbyterian Hospital offers patients the latest tools for the   assessment of mesothelioma. Under the aegis of the Mesothelioma Center, more than 100 newly   diagnosed patients with mesothelioma are cared for and followed each   year from all over the country. (The total number of new cases in the   U.S. is less than 3,000 per year). Most patients are seen or treated by a   surgeon, medical oncologist, and radiotherapist during their course, as   well as a highly specialized nursing staff and psychiatry liaison.</p>
<p>Drs. Valerie Rusch and Raja Flores<br />
Memorial Sloan-Kettering<br />
1275 York Avenue<br />
New York, NY 10021<br />
1-(212)-639-2806</p>
<p><a href="http://www.mskcc.org/mskcc/html/76962.cfm">Memorial Sloan-Kettering</a>&#8216;s team of mesothelioma experts makes treatment recommendations  on an   individual basis, taking into account the stage of the cancer, the   patient&#8217;s general health, and, for patients with pleural mesothelioma,   how well the lungs function. Patients who are otherwise in overall good   health and who have early-stage mesothelioma may be treated with   chemotherapy, followed by surgery and radiation. Patients who cannot   tolerate surgery or who have more advanced disease are generally treated   with chemotherapy alone. Memorial Sloan-Kettering is researching novel   treatments for mesothelioma, and participation in a clinical trial may   be offered.</p>
<p>Herbert Irving Comprehensive Cancer Center<br />
622 West 168th Street<br />
New York, NY 10032<br />
1-(212)-305-9327</p>
<p><a href="http://hiccc.columbia.edu/">Herbert Irving Comprehensive Cancer Center</a> of Columbia University is dedicated to the cure of cancer through   innovative research, training of researchers and clinicians, and   outstanding patient care. The HICCC has been a National Cancer Institute   (NCI)-designated cancer center for over 30 years, and is one of only 39   NCI-designated cancer centers in the nation. In partnership with <a href="http://www.nyp.org/" target="_blank">NewYork-Presbyterian   Hospital</a>, the cancer center is ranked as one of the top hospitals in the United States. The internationally-recognized researchers and clinicians of the HICCC   bring together the best approaches for prevention, diagnosis and   treatment of all types of cancer.</p>
<p>Roswell Park Cancer Institute<br />
Elm and Carlton Streets<br />
Buffalo, NY. 14263<br />
1-(212)-ROSWELL</p>
<p><a href="http://www.roswellpark.org/">Roswell Park Cancer Institute</a> identified cancer   research as the core element of its mission. Groundbreaking research by   RPCI scientists has led to greater understanding of cancer and to major   advances in diagnosis and treatment.</p>
<p>Arthur G. James Cancer Hospital<br />
The Ohio State University Comprehensive Cancer Center</p>
<p>300 W. 10th Avenue<br />
Columbus, OH 43210<br />
1-(800)-293-5066</p>
<p><a href="http://cancer.osu.edu/Pages/index.aspx">Arthur G. James Cancer Hospital</a> is one of the nation’s leading   			comprehensive cancer centers, finding groundbreaking discoveries that are   			changing the way the world diagnoses, treats and prevents cancer. They are the only freestanding cancer   			hospital in the Midwest, and their cancer experts offer leading-edge   			cancer treatments tailored to individual patients because no two   			cancers, or two patients, are alike.</p>
<p>Case Western Reserve University Hospitals<br />
Wearn 152, 11000 Euclid Avenue<br />
Cleveland, OH. 44106<br />
1-(216)-844-8797</p>
<p><a href="http://cancer.case.edu/">The Case Comprehensive Cancer Center</a> (Case CCC) based at Case Western   Reserve University (CWRU) is a partnership organization supporting all   cancer related research efforts at CWRU, University Hospitals Case   Medical Center, and the Cleveland Clinic. Located in Cleveland, Ohio,   the Case CCC serves the cancer research and clinical needs of an urban   manufacturing and rural agricultural region containing 3.8 million   people in Northern Ohio.</p>
<p>Dr. David P. Mason<br />
Cleveland Clinic Foundation<br />
9500 Euclid Avenue<br />
Cleveland, OH 44195<br />
1-(216)-444-4053</p>
<p><a href="http://my.clevelandclinic.org/about/default.aspx">Cleveland Clinic Foundation</a>was founded in 1921 by four renowned physicians with a   vision of providing outstanding patient care based upon the principles   of cooperation, compassion and innovation. <em>U.S. News &amp; World   Report </em>consistently names Cleveland Clinic as one of the nation’s   best hospitals in its annual “America’s Best Hospitals” survey.</p>
<p>Dr. Daniel Sterman<br />
University of Pennsylvania Cancer Center<br />
3400 Spruce Street<br />
Philadelphia, PA. 19104<br />
1-(215)-614-0984</p>
<p><a href="http://www.penncancer.org/">University of Pennsylvania Cancer Center</a>provides the full spectrum of treatment of mesothelioma and rare cancers as well as follow-up care. The goal of their cancer treatment center is to eliminate cancer and prevent or reduce the chance of recurrence in the future. They offer various types of cancer therapy, alone or in combinations,   depending on the type of cancer as well as other factors, such as stage   of tumor, and your medical condition. Your physicians at the University of Pennsylvania will recommend the   best combination of treatments for your individual condition and assist   in making the choice that&#8217;s right for you.</p>
<p>Dr. Joseph S. Friedberg<br />
UPenn at Presybterian<br />
39th and Market Streets<br />
Philadelphia, PA. 19104<br />
1-(215)-662-9195</p>
<p><a href="http://www.pennmedicine.org/">The Abramson Cancer Center at Penn Presbyterian                                  Medical Center</a> offers patients the   latest advances                                  in the prevention, diagnosis and   treatment of                                  cancer. Their doctors work closely with   other                                  cancer specialists to provide   comprehensive,                                  integrated care. Other caregivers who   may                                  become involved in your care are doctors   and                                  nurses in surgical oncology, radiation   oncology,                                  gynecologic oncology, urology, radiology   and                                pathology.</p>
<p>Fox Chase Cancer Center<br />
333 Cottman Avenue<br />
Philadelphia, PA. 19111<br />
1-(888)-FOX-CHASE</p>
<p><a href="http://www.fccc.edu/cancer/types/lung/mesothelioma.html">Fox Chase Cancer Center</a>&#8216;s surgeons, <a href="http://www.fccc.edu/physicians/surgical/scott.html">Walter   J. Scott, MD, FACS</a> and <a href="http://www.fccc.edu/physicians/surgical/lebenthal.html">Abraham   &#8220;Avi&#8221; Lebenthal, MD</a>, offer an individualized tailored surgical   approach to the treatment of mesothelioma that integrates the patient functional status and stage.   Surgery is often augmented by adjuvant Radiation followed by   chemotherapy.</p>
<p>University of Pittsburgh Cancer Institute<br />
5115 Centre Avenue<br />
Pittsburgh, PA 15232<br />
1-(800)-237-4PCI</p>
<p><a href="http://www.upci.upmc.edu/">University of Pittsburgh Cancer Institute</a> is the only National Cancer Institute (NCI)-designated Comprehensive   Cancer Center in western Pennsylvania.  With more than 625 research   faculty members specializing in disciplines ranging from cancer   prevention and early detection to novel therapeutic discovery,   survivorship, and end of life care, UPCI maintains a broad strategic   vision and comprehensive approach to understanding and defeating cancer.    In 2007, UPCI received nearly $200 million in research grants, and was   ranked 11th nationally in funding from the National Cancer Institute.</p>
<p>Dr. David C. Rice<br />
The University of Texas<br />
MD Anderson Cancer Center<br />
1515 Holcombe Blvd<br />
Houston, TX 77030<br />
1-(713)-794-1477</p>
<p>At the University of Texas, the <a href="http://www.mdanderson.org/about-us/index.html">MD Anderson Cancer Center</a>&#8216;s mission is to eliminate cancer in Texas, the nation, and the world through   outstanding programs that integrate patient care, research and   prevention, and through education for undergraduate and graduate   students, trainees, professionals, employees and the public.</p>
<p>Dr. J Michael DiMaio<br />
UT Southwestern Medical Center<br />
5323 Harry Hines Blvd<br />
Dallas, TX. 75390-8879<br />
1-(214)-645-7731</p>
<p>The <a title="Harold C. Simmons Comprehensive Cancer   Center" href="http://www.utsouthwestern.edu/utsw/home/simmons/index.html" target="_blank">Harold   C. Simmons Comprehensive Cancer Center</a> at UT Southwestern Medical   Center is one of the premier centers in the nation for the study and   treatment of cancer. Their commitment to furthering the science of cancer   research has enabled the cancer program to achieve dramatic results in   UT Southwestern laboratories and health-care facilities.<br />
Established in 1989 through a generous gift from Dallas philanthropist   Harold C. Simmons, the <a title="Simmons Comprehensive   Cancer Center" href="http://www.utsouthwestern.edu/utsw/home/simmons/index.html" target="_blank">Simmons   Comprehensive Cancer Center</a> offers a broad-based collection of   cancer programs, each providing a wide range of patient-care services.   The program receives significant support from the most prestigious   cancer research institutions in the nation: the National Cancer   Institute, the American Cancer Society, the National Institutes of   Health, the Susan G. Komen Foundation, the Lance Armstrong Foundation   and the Centers for Disease Control and Prevention.</p>
<p>Dr. Roy Smythe<br />
Scott &amp; White<br />
2401 South 31st Street<br />
Temple, TX 76508<br />
1-(254)-724-2595</p>
<p><a href="http://www.sw.org/web/patientsAndVisitors">Scott &amp; White</a> is committed to patient care, education and research, which has earned their health system a reputation for excellence in cancer, orthopedics and   cardiovascular care. Their dedicated physicians have built a   nationally-acclaimed health care organization, recognized by   organizations including <em>U.S. News &amp; World Report</em> and <em>Newsweek</em>.   And for the tenth year, Scott &amp; White Memorial Hospital is listed   among the <a href="http://www.sw.org/web/patientsAndVisitors/iwcontent/public/newsroom/en_us/html/newsroom_PRTop100Reuters20091118.html">&#8220;Top   100 Hospitals&#8221; in America for cardiovascular care</a>.</p>
<p>San Antonio Cancer Institute<br />
7703 Floyd Curl Drive<br />
San Antonio, TX. 78229<br />
1-(210)-616-5590</p>
<p><a href="http://www.ctrc.net/ctrc_home.cfm?db_content=home">San Antonio Cancer Therapy and Research Center&#8217;s </a>total patient care system consists of break-through   researchers, state-of-the-art tools and technology and multidisciplinary   clinical care, delivered through a team of world-class physicians,   laboratory scientists and other medical professionals. The total patient care system allows the center to   seamlessly translate the latest research findings more efficiently and   directly to patients. They treat the cancer, and care for the patient. Their team of scientists and doctors are committed to conquering cancer one   patient at a time.</p>
<p>Vermont Cancer Center<br />
89 Beaumont Avenue<br />
Burlington, VT 05405<br />
1-(802)-656-4414</p>
<p><a href="http://vermontcancer.org/">Vermont Cancer Center</a> is  a not-for-profit comprehensive clinical and   research cancer center; the only such organization in the state of   Vermont. Founded in 1974, the Vermont Cancer Center is located within   the University of Vermont (UVM) College of Medicine and enjoys a   clinical partnership with Fletcher Allen Health Care, Vermont&#8217;s academic   medical center with UVM. The Vermont Cancer Center is committed to innovative cancer research,   life-saving prevention and treatment programs, public education and   scientific collaboration, and serves to influence standards of cancer   prevention, screening, diagnosis and care across Vermont and northern   New York.</p>
<p>Dr. Eric Vallieres<br />
University of Washington Medical Center<br />
1959 NE Pacific<br />
Seattle, WA 98195<br />
1-(206)-598-4477</p>
<p><a href="http://www.amh.org">University of Washington Medical Center</a> is a   fully accredited, not-for-profit, regional teaching hospital. Located at   1200 Old York Road (Route 611) in Abington, PA, AMH has been providing   comprehensive, high-quality services for people in Montgomery, Bucks and   Philadelphia counties for more than 90 years.</p>
<p>Fred Hutchinson Cancer Research Center<br />
1100 Fairview Avenue N<br />
Seattle, WA 98109<br />
1-(206)-667-5000</p>
<p><a href="http://www.fhcrc.org/index.html">The Fred Hutchinson Cancer Research Center</a>, together with its clinical and research partners,   the University of Washington, Seattle Children&#8217;s and the Seattle Cancer   Care Alliance, comprise the <a href="http://www.cancerconsortium.org/">Fred   Hutchinson/University of Washington Cancer Consortium</a>. The   Consortium is among 40 National Cancer Institute-designated <a href="http://www3.cancer.gov/cancercenters/description.html">comprehensive   cancer centers</a> nationwide. Their interdisciplinary teams of world-renowned scientists and humanitarians   work together to prevent, diagnose and treat cancer, HIV/AIDS and other   diseases. Their researchers, including three <a href="http://www.fhcrc.org/research/nobel/">Nobel laureates</a>, bring a   relentless pursuit and passion for health, knowledge and hope to their   work and the world.</p>
<p>Seattle Cancer Care Alliance<br />
825 Eastlake Avenue E<br />
Seattle, WA 98109<br />
1-(206)-288-1024</p>
<p><a href="http://www.seattlecca.org/default.cfm">Seattle Cancer Care Alliance</a> unites the doctors from Fred Hutchinson Cancer Research Center, UW   Medicine, and Seattle Children&#8217;s to form a world-class treatment center   that  provides advanced therapies and clinical studies for cancers and   other related diseases.</p>
<p>University of Michigan<br />
Comprehensive Cancer Center<br />
600 Highland Avenue<br />
Madison, WI 53792-6164<br />
1-(800)-622-8922</p>
<p><a href="http://www.cancer.med.umich.edu/index.html">Comprehensive Cancer Center</a> at the University of Michigan is one of only 40 U.S. centers to earn the <a href="http://www.cancer.gov"> National Cancer Institute&#8217;s</a> &#8220;Comprehensive&#8221;   designation by meeting strict guidelines for extensive, interactive and innovative clinical and laboratory   research; participation in NCI testing of new therapies; significant cancer prevention and control research; provision of patient education, community service and outreach as   well as training for health professionals. The Cancer Center is also a founding member of the <a href="http://www.nccn.org/index.asp"> National Comprehensive Cancer Network</a>, a consortium of 21 premiere   cancer centers   formed to develop national guidelines to ensure consistent, high-quality   and cost-effective cancer care.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.mesotheliomalegalblog.com/2009/05/mesothelioma-treatment-centers-by-state/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

